A Phase I Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults with Newly Diagnosed Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD)
A Study of CYNK-001 in Adults with Newly Diagnosed Acute Myeloid Leukemia
Sponsor: Celularity, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS8676
U.S. Govt. ID: NCT04310592
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this clinical research study is to evaluate the safety (any good or bad effects) of CYNK-001 and to assess the effects of CYNK-001 on your Acute Myeloid Leukemia (AML). Also, the study plans to determine the maximum tolerated dose (highest safe dose) of CYNK-001 and assess whether CYNK-001 can eliminate your residual (leftover) disease. CYNK-001 has not been approved by the FDA for the treatment of cancer or any other disease and its use in this study is investigational. About 22 patients in the US will take part in this study.
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Are you between 18 and 75 years of age? Yes No
Do you have newly diagnosed Acute Myeloid Leukemia (AML)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE